enzh-TWfrdeitjaptrues

Abnormal Splicing Patterns and Novel Intron Retentions Affect Genes Regulating Splicing, NF-Kb, ERK1/2, and TP53 in WM

The 59th Annual ASH meeting & exposition was held was held December 9-12, 2017 in Atlanta, GA. The following are the 16 posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.

Click on the poster to download a full size PDF version. For more information about ASH-2017, please visit http://www.hematology.org/Annual-Meeting/

 

Acquired Von Willebrand Disease in Patients with Waldenstrom Macroglobulinemia

Acquired Von Willebrand Disease in Patients with Waldenstrom Macroglobulinemia

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau, Patricia Severns, Steven P. Treon

 

Aberrant HCK Survival Signaling By Mutated MYD88 Requires PAX5 in Waldenstrom's Macroglobulinemia and ABC DLBCL Cells

Aberrant HCK Survival Signaling By Mutated MYD88 Requires PAX5 in Waldenstrom's Macroglobulinemia and ABC DLBCL Cells

Xia Liu, Jiaji Chen, Manit Munshi, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Amanda Kofides, Gloria Chan, Zachary Hunter, Christopher Patterson, Robert Manning, Philip Brodsky, Joshua Gustine, Patricia Severns, Toni Dubeau, Jorge Castillo, Steven Treon, and Guang Yang

 

Mutated MYD88 Homozygosity Is Increased in Previously Treated Patients with Waldenstrom's Macroglobulinemia, and Associates with CXCR4 Mutation Status and Ibrutinib Exposure

Mutated MYD88 Homozygosity Is Increased in Previously Trated Patients with Waldenstrom's Macroglobulinemia, and Associates with CXCR4 Mutation Status and Ibrutinib Exposure

Nickolas Tsakmaklis, Lian Xu, Joshua Gustine, Robert J. Manning, Guang Yang, Jie Chen, Xia Liu, Jiaji Chen, Maria Demos, Gloria G. Chan, Christopher J. Patterson, Jorge J. Castillo, Steven P. Treon and Zachary R. Hunter

 

Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenstrom's Macroglobulinemia

Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenstrom's Macroglobulinemia

Jorge J. Castillo, Kirsten Meid, Joshua N. Gustine, Toni E. Dubeau, Patricia Severns, Steven P. Treon

 

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline WM

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline WM

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau, Patricia Severns, Steven P. Treon

 

Mutated MYD88 Activates the BCR Component SYK and Provides a Rationale Therapeutic Target in WM

Mutated MYD88 Activates the BCR Component SYK and Provides a Rationale Therapeutic Target in WM

Manit Munshi, Xia Liu, Jiaji Chen, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Gloria Chan, Zachary R. Hunter, Christopher J. Patterson, Robert Manning, Philip Brodsky, Joshua Gustine, Patricia Severns, Toni Dubeau, Jorge J. Castillo, Steven P. Treon, and Guang Yang

 

Long-Term Follow-Up of Previously Treated Patients Who Received Ibrutinib for Symptomatic WM: Update of Pivotal Clinical Trial

Long-Term Follow-Up of Previously Treated Patients Who Received Ibrutinib for Symptomatic WM: Update of Pivotal Clinical Trial

Steven P. Treon, Kirsten Meid, Joshua Gustine, Kurt S. Bantilan, Toni Dubeau, Patricia Severns, Guang Yang, Lian Xu, Christopher Patterson, Irene M. Ghobrial, Jacob Laubach, Zachary R. Hunter, Jorge J. Castillo, Maria L. Palomba, and Ranjana H. Advani.

 

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic WM

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic WM

Steven P. Treon, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, Christopher Patterson, Lian Xu, Guang Yang, Maria Demos, Amanda Kofides, Jiaji Chen, Manit Munshi, Nickolas Tsakmaklis, Gloria Chan, Andrew Yee, Noopur Raje, Elizabeth O'Donnell, Zachary R. Hunter, and Jorge Castillo

 

Long-Term Analysis of a Prospective Phase II Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in WM

Long-Term Analysis of a Prospective Phase II Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in WM

Kirsten Meid, MPH, , Toni Dubeau, NP, Patricia Severns, NP, Joshua Gustine, MPH, Irene M. Ghobrial, MD, Jorge J. Castillo, MD, and, Steven P. Treon, MD, PhD, Bing Center for Waldenstrom’s Macroglobulinemia at the Dana-Farber

 

Abnormal Splicing Patterns and Novel Intron Retentions Affect Genes Regulating Splicing, NF-Kb, ERK1/2, and TP53 in WM

Abnormal Splicing Patterns and Novel Intron Retentions Affect Genes Regulating Splicing, NF-Kb, ERK1/2, and TP53 in WM

Zachary R. Hunter, Nickolas Tsakmaklis, Lian Xu, Maria Demos, Amanda Kofides, Gloria G. Chan, Jiaji Chen, Manit Munshi, Xia Liu, Joshua Gustine, Christopher J. Patterson, Toni Dubeau, Patricia Severns, Jorge Castillo, Guang Yang, Nikhil Munshi, Kenneth Anderson and Steven P. Treon

 

MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in WM

MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in WM

Steven P. Treon, Zachary R. Hunter, Joshua Gustine, Kirsten Meid, Lian Xu, Xia Lu, Guang Yang, Manit Munshi, Robert Manning, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Jiaji Chen, Christopher J. Patterson, Toni Dubeau, Patricia Severns, and Jorge J. Castillo.

 

The Genomic Landscape of MYD88 Wild-Type WM Is characterized By Somatic Mutations in TBL1XR1, the CBM Complex, and NFKB2

The Genomic Landscape of MYD88 Wild-Type WM Is characterized By Somatic Mutations in TBL1XR1, the CBM Complex, and NFKB2

Zachary Hunter, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Lian Xu, Gloria Chan, Jiaji Chen, Manit Munsh, Xia Liu, Joshua Gustine, Christopher Patterson, Toni Dubeau, Patricia Severns, Jorge J. Castillo, Guang Yang and Steven P Treon

 

Survival Rates and Clinical Characteristics of Young Patients with WM

Survival Rates and Clinical Characteristics of Young Patients with WM

Amaara Babwah, MS, Joshua Gustine, MPH, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P. Treon, MD, PhD and Jorge J. Castillo, MD

 

Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated WM

Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated WM

Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, M. Lia Palomba, Ranjana H. Advani, Steven P. Treon, and Jorge J. Castillo

 

Patient-reported Symptoms during Ibrutinib Holds: A Withdrawal Syndrome

Patient-reported Symptoms during Ibrutinib Holds: A Withdrawal Syndrome

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, and Steven P. Treon

 

Differential Diagnosis of Suspected MYD88 Wild_Type WM Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma

Differential Diagnosis of Suspected MYD88 Wild_Type WM Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma

Steven P. Treon, Zachary R. Hunter, Joshua Gustine, Kirsten Meid, Lian Xu, Xia Lu, Guang Yang, Manit Munshi, Robert Manning, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Jiaji Chen, Christopher J. Patterson, Toni Dubeau, Patricia Severns, and Jorge Castillo.

 

Latest Bing Center News

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Researchers say ibrutinib seems to protect those with COVID-19 from lung damage and respiratory distress. They will now conduct a trial to see if the medication can reduce a patient’s need for a ventilator, improve survival and reduce their time in the hospital.

Read more..

COVID-19 Information for Our Patients

COVID-19 Information for Our Patients

The Bing Center would like to share this important information with all of our patients and interested parties to help us all manage through this unprecedented crisis in the best and most productive way possible.

Read more..

Waldenström Macroglobulinemia Specialty Channel

Waldenström Macroglobulinemia Specialty Channel

Welcome to the Oncology Learning Network Waldenstrom Macroglobulinemia Specialty Channel. Here you will find articles dedicated to the research and treatment of WM.

Read more..

Dana-Farber to Test Blood Cancer Drug in COVID-19

Dana-Farber to Test Blood Cancer Drug in COVID-19

Scientists at Dana-Farber have launched a clinical test of a blood-cancer drug in patients that have the COVID-19 virus. The test follows several case reports in which the drug, ibrutinib, appeared to protect against lung damage and respiratory distress caused by the novel virus.

Read more..

BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™

Read more..

Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies

Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies

We are excited to announce this new webcast on diagnosis, risk stratification, and current and emerging therapies for Waldenström's Macroglobulinemia (WM).

Read more..

Watch Dr. Jorge Castillo’s engaging “Ask the Doctor” session

Watch Dr. Jorge Castillo’s engaging “Ask the Doctor” session

Fifty WMers from the Philly WM Support Group enjoyed a lively, engaging and informative conversation with Dr. Jorge Castillo, Clinical Director of the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute.

Read more..

Drs. Castillo and Kastritis have joined the IWMF Scientific Advisory Committee

Drs. Castillo and Kastritis have joined the IWMF Scientific Advisory Committee

The IWMF is proud to welcome two new members to its Scientific Advisory Committee (SAC) chaired by Dr. Steven Ansell of the Mayo Clinic and Dr. Stephen Treon of the Dana-Farber Cancer Institute. The new members, Dr. Jorge Castillo from Dana-Farber, Boston, USA, and Dr. Efstathios Kastritis of Athens, Greece, were invited to participate because of their expertise in specific research areas identified by the IWMF-LLS Strategic Research Roadmap for WM.

Read more..

Waldenstrom's Song - Tim Salz, UC Berkeley, CA

Waldenstrom's Song - Tim Salz, UC Berkeley, CA

This is a song I wrote for all of my fellow Wallies out there. Thanks for watching.

Read more..

Robert J. Manning, FM, RNG

Robert J. Manning, FM, RNG

I first met Bob Manning in early 2004 when I started volunteering at the Bing Center. My boss introduced me to Bob, and said 3 words, "Help this guy". The first thing I noticed was Bob's badge, which contained his name, followed by the credentials, FM, RNG. Bob told me they meant, "Former Marine, Real Nice Guy". That's when I knew this wasn't going to be a boring relationship.

Read more..